Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
RIGL's Cash to Debt is ranked higher than
98% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. RIGL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RIGL' s Cash to Debt Range Over the Past 10 Years
Min: 4.48  Med: 65.70 Max: No Debt
Current: No Debt
Equity to Asset 0.69
RIGL's Equity to Asset is ranked higher than
60% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. RIGL: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
RIGL' s Equity to Asset Range Over the Past 10 Years
Min: 0.43  Med: 0.75 Max: 0.94
Current: 0.69
0.43
0.94
Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
98% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. RIGL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RIGL' s Interest Coverage Range Over the Past 10 Years
Min: 388.1  Med: 10000.00 Max: 9999.99
Current: No Debt
388.1
9999.99
F-Score: 3
Z-Score: -7.15
M-Score: -1.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -214.50
RIGL's Operating margin (%) is ranked lower than
92% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. RIGL: -214.50 )
Ranked among companies with meaningful Operating margin (%) only.
RIGL' s Operating margin (%) Range Over the Past 10 Years
Min: -14938.27  Med: -1106.05 Max: 28.25
Current: -214.5
-14938.27
28.25
Net-margin (%) -213.40
RIGL's Net-margin (%) is ranked lower than
92% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. RIGL: -213.40 )
Ranked among companies with meaningful Net-margin (%) only.
RIGL' s Net-margin (%) Range Over the Past 10 Years
Min: -14872.93  Med: -1101.92 Max: 30.31
Current: -213.4
-14872.93
30.31
ROE (%) -52.20
RIGL's ROE (%) is ranked lower than
89% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. RIGL: -52.20 )
Ranked among companies with meaningful ROE (%) only.
RIGL' s ROE (%) Range Over the Past 10 Years
Min: -142.04  Med: -48.39 Max: 27.46
Current: -52.2
-142.04
27.46
ROA (%) -39.61
RIGL's ROA (%) is ranked lower than
89% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. RIGL: -39.61 )
Ranked among companies with meaningful ROA (%) only.
RIGL' s ROA (%) Range Over the Past 10 Years
Min: -101.94  Med: -39.35 Max: 23.14
Current: -39.61
-101.94
23.14
ROC (Joel Greenblatt) (%) -2763.15
RIGL's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. RIGL: -2763.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RIGL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4317.77  Med: -1835.84 Max: 1113
Current: -2763.15
-4317.77
1113
Revenue Growth (3Y)(%) 4.00
RIGL's Revenue Growth (3Y)(%) is ranked lower than
56% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. RIGL: 4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RIGL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -52.10 Max: 75.5
Current: 4
0
75.5
EBITDA Growth (3Y)(%) -8.80
RIGL's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. RIGL: -8.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RIGL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.1  Med: -21.70 Max: 23.2
Current: -8.8
-47.1
23.2
EPS Growth (3Y)(%) -8.60
RIGL's EPS Growth (3Y)(%) is ranked lower than
69% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. RIGL: -8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RIGL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.5  Med: -21.50 Max: 21.8
Current: -8.6
-56.5
21.8
» RIGL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

RIGL Guru Trades in Q1 2015

Paul Tudor Jones 13,814 sh (New)
Charles Brandes 44,700 sh (New)
Chuck Royce Sold Out
Jim Simons 100,900 sh (-80.47%)
» More
Q2 2015

RIGL Guru Trades in Q2 2015

Jim Simons 254,000 sh (+151.73%)
Paul Tudor Jones 18,713 sh (+35.46%)
Charles Brandes 44,700 sh (unchged)
» More
Q3 2015

RIGL Guru Trades in Q3 2015

Jim Simons 398,600 sh (+56.93%)
Paul Tudor Jones 18,913 sh (+1.07%)
Charles Brandes 25,000 sh (-44.07%)
» More
Q4 2015

RIGL Guru Trades in Q4 2015

Jim Simons 499,600 sh (+25.34%)
Charles Brandes 25,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.27
RIGL's P/B is ranked higher than
54% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. RIGL: 2.27 )
Ranked among companies with meaningful P/B only.
RIGL' s P/B Range Over the Past 10 Years
Min: 1.02  Med: 2.54 Max: 12.78
Current: 2.27
1.02
12.78
P/S 7.72
RIGL's P/S is ranked lower than
94% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. RIGL: 7.72 )
Ranked among companies with meaningful P/S only.
RIGL' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 32.91 Max: 489.5
Current: 7.72
2.8
489.5
EV-to-EBIT -1.71
RIGL's EV-to-EBIT is ranked lower than
99.99% of the 824 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.49 vs. RIGL: -1.71 )
Ranked among companies with meaningful EV-to-EBIT only.
RIGL' s EV-to-EBIT Range Over the Past 10 Years
Min: -34  Med: -2.40 Max: 9.5
Current: -1.71
-34
9.5
EV-to-EBITDA -1.75
RIGL's EV-to-EBITDA is ranked lower than
99.99% of the 862 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.85 vs. RIGL: -1.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
RIGL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.4  Med: -2.40 Max: 9.1
Current: -1.75
-41.4
9.1
Current Ratio 3.91
RIGL's Current Ratio is ranked higher than
73% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. RIGL: 3.91 )
Ranked among companies with meaningful Current Ratio only.
RIGL' s Current Ratio Range Over the Past 10 Years
Min: 1.84  Med: 8.27 Max: 36.3
Current: 3.91
1.84
36.3
Quick Ratio 3.91
RIGL's Quick Ratio is ranked higher than
78% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. RIGL: 3.91 )
Ranked among companies with meaningful Quick Ratio only.
RIGL' s Quick Ratio Range Over the Past 10 Years
Min: 1.84  Med: 8.27 Max: 36.3
Current: 3.91
1.84
36.3
Days Sales Outstanding 2.08
RIGL's Days Sales Outstanding is ranked higher than
98% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. RIGL: 2.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
RIGL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.04  Med: 23.19 Max: 293.53
Current: 2.08
12.04
293.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.40
RIGL's Price/Net Cash is ranked higher than
85% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.83 vs. RIGL: 2.40 )
Ranked among companies with meaningful Price/Net Cash only.
RIGL' s Price/Net Cash Range Over the Past 10 Years
Min: 1.2  Med: 3.47 Max: 15.44
Current: 2.4
1.2
15.44
Price/Net Current Asset Value 2.33
RIGL's Price/Net Current Asset Value is ranked higher than
87% of the 630 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.78 vs. RIGL: 2.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RIGL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.2  Med: 3.26 Max: 13.37
Current: 2.33
1.2
13.37
Price/Tangible Book 2.27
RIGL's Price/Tangible Book is ranked higher than
72% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. RIGL: 2.27 )
Ranked among companies with meaningful Price/Tangible Book only.
RIGL' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 2.90 Max: 11.65
Current: 2.27
1.16
11.65
Price/Median PS Value 0.23
RIGL's Price/Median PS Value is ranked higher than
97% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.11 vs. RIGL: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
RIGL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.80 Max: 28.82
Current: 0.23
0.04
28.82
Earnings Yield (Greenblatt) (%) -58.50
RIGL's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. RIGL: -58.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RIGL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 10.5  Med: 15.50 Max: 6128.3
Current: -58.5
10.5
6128.3

More Statistics

Revenue(Mil) $29
EPS $ -0.71
Beta1.51
Short Percentage of Float2.84%
52-Week Range $2.21 - 5.20
Shares Outstanding(Mil)88.53

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RI2A.Germany,
Rigel Pharmaceuticals Inc was incorporated in the state of Delaware on June 14, 1996. The Company is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Companys pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor entering in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo, respectively. The Company is conducting proprietary research in the broad disease areas of inflammation/immunology and muscle wasting/muscle endurance. The Companys major competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 29 2016
Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT) Jan 28 2016
Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT) Jan 28 2016
Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare... Jan 07 2016
Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare... Jan 07 2016
Direction of Market Influences - Free Research on Rex Energy, Kratos Defense and Security Solutions,... Dec 15 2015
Is XenoPort, Inc. (XNPT) A Good Stock To Buy? Dec 14 2015
RIGEL PHARMACEUTICALS INC Financials Dec 08 2015
What Do Hedge Funds Think of Wi-LAN Inc – US listing (WILN)? Nov 29 2015
A look at Equity Market Momentum - Research on Telecommunication Systems, Rigel Pharmaceuticals,... Nov 18 2015
Edited Transcript of RIGL earnings conference call or presentation 3-Nov-15 10:00pm GMT Nov 04 2015
Rigel reports 3Q loss Nov 03 2015
Rigel reports 3Q loss Nov 03 2015
Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today Nov 03 2015
Rigel Announces Third Quarter 2015 Financial Results Nov 03 2015
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2015
Rigel Announces Third Quarter 2015 Financial Results Nov 03 2015
Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results Oct 27 2015
Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results Oct 27 2015
Rigel Pharmaceuticals, Inc. Earnings Q2, 2015 Sep 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK